ADT lowers testosterone levels, which prevents androgen receptor signalling; however, GnRH agonists and antagonists suppress testosterone levels through different mechanisms, which may confer different CV risk as measured by event rates for patients with prostate cancer who receive ADT. The gene discussed is GNRH1; the disease is prostate carcinoma.